Quanterix (QTRX) Q1 2025: Akoya Deal Cut by 67% as Academic and Pharma Headwinds Deepen

2025-05-12 | By EarningsIQ Research

Quanterix’s Q1 revealed persistent macro headwinds, but also showcased record consumables strength and a dramatically restructured Akoya merger, signaling a pivot toward scale and resilience. With academic funding and pharma spend both tightening, management is leaning on recurring consumables, new assay launches, and cost discipline, while betting the Akoya deal and Samoa One platform will expand market reach and future-proof the business.

Summary

  • Akoya Merger Restructured: Deal value was slashed and Quanterix’s stake increased, reflecting market caution and a drive for synergy.
  • Consumables Outperform Amid Capital Constraints: Recurring revenue from new neurology and immunology assays offset softness in instruments and accelerator projects.
  • 2025 Guide Cut Sharply: Management bakes in deep academic and pharma funding risk, but targets cash flow breakeven in 2026 via cost actions and expanded platform reach.

Performance Analysis

Quanterix posted Q1 revenue of $30.3 million, down 5% year-over-year, with the headline decline masking a record quarter for consumables, which rose 6% and now anchor the company’s recurring revenue base. Instrument revenue ticked up slightly, but capital equipment sales remain pressured, reflecting the broader funding squeeze in both academia and biopharma. Accelerator lab revenue, a lumpy and high-margin segment, fell 36% due to the absence of large pharma projects and the end of key collaborations, notably with Lilly.

Adjusted gross margin landed at 50%, impacted by non-cash inventory charges and revenue mix shift away from high-margin accelerator work. Cash burn improved materially, with adjusted usage halved to $9 million versus last year, reflecting early benefits from cost discipline and lower one-time outflows. Geographically, North America led modest growth, while Europe lagged on lower accelerator activity. The company ended the quarter with a robust $269 million in liquidity, but expects this to drop post-Akoya deal and one-time payments.

  • Consumables Strength: New neurology and inflammation assays drove record consumables sales, providing a recurring buffer against capital demand volatility.
  • Accelerator Volatility: Pharma project delays and smaller ticket sizes weighed on accelerator revenue, with visibility limited for large deals in the pipeline.
  • Cost Actions Bite: Over 50% reduction in cash burn YoY, with further $30 million in core cost cuts announced and $55 million targeted for 2026.

Overall, Quanterix’s mix is shifting toward consumables and menu innovation as capital and project cycles slow, while the Akoya merger and Samoa One launch are positioned as catalysts for scale and platform leverage.

Executive Commentary

"First quarter results exceeded our expectations, highlighting the resilience of our instruments and consumables business and strengthening our confidence in the long-term growth potential. While the quarter was stable, we have revised our guidance more conservatively to account for the broader macrofunding environment rather than any company-specific factors."

Masood Tulloo, President and Chief Executive Officer

"Adjusted cash burned during the quarter was $9 million, compared to adjusted cash burn of $19.4 million in the prior year, a reduction of over 50% in our cash burn. We expect to achieve cash flow breakeven as a combined company in 2026, and we expect to have north of $100 million of cash on the balance sheet with no debt as we exit 2026."

Vandana Sriram, Chief Financial Officer

Strategic Positioning

1. Akoya Merger Reset and Synergy Focus

The Akoya Biosciences merger was dramatically restructured, with the equity value cut by 67% to $66 million and Quanterix’s ownership rising to 84%. This reflects both a more conservative market environment and a sharpened focus on synergy: Akoya is expected to contribute 37% of combined top-line and 40% of gross profit dollars, with immediate expansion of the installed instrument base and addressable market from $1 billion to $5 billion. The deal is positioned as a lever for cross-platform biomarker solutions, especially in oncology and immunology, and as a means to accelerate menu expansion and customer reach.

2. Menu Expansion and Consumables Recurrence

Quanterix is doubling down on assay innovation, launching four new immunology assays in Q1 and building on 20 launches last year. The GrowMenu initiative is driving record consumables revenue, reinforcing the company’s leadership in neurology and pushing into inflammation and oncology. With over 1,000 instruments in the field, the company is prioritizing recurring reagent sales and menu breadth to offset lumpy capital and accelerator cycles.

3. Samoa One Platform and Flow Cytometry Unlock

The upcoming Samoa One platform is a cornerstone bet, promising 10x sensitivity, expanded multiplexing (up to 10-plex), and code-matched barcoding. Critically, Quanterix will offer Samoa One assay kits compatible with over 20,000 existing flow cytometers, democratizing access and sidestepping capital budget hurdles. This reagent-first approach is designed to rapidly scale the user base and consumables pull, especially in immunology and oncology, where flow is already entrenched.

4. Alzheimer’s Diagnostics and Lucent AD Complete

Alzheimer’s diagnostics remain a top strategic priority, with the PTAU217 blood test now offered at ARUP Laboratories, and the multi-marker Lucent AD Complete test progressing through four clinical trials. Management expects multi-marker reimbursement in early 2026, with the test differentiated by algorithmic risk scoring and reduced intermediate zones, aiming to outperform both single-marker and mass spec competitors.

5. Operational Discipline and Cost Structure Reset

Facing macro headwinds, Quanterix is executing $30 million in core cost cuts for 2025, scaling to $55 million in annualized savings by 2026. These actions, combined with post-merger synergy, are targeted to achieve cash flow breakeven next year and maintain a debt-free balance sheet above $100 million.

Key Considerations

This quarter underscores a pivotal transition for Quanterix: the business is shifting from high-growth, project-driven cycles to a more resilient, recurring consumables and platform model, while using the Akoya merger and menu innovation to buffer against cyclical funding risk.

Key Considerations:

  • Recurring Revenue as Buffer: Menu-driven consumables growth is now the primary stabilizer as instruments and accelerator remain volatile.
  • Merger Synergy and Market Expansion: Akoya integration expands installed base and cross-sell opportunity, but execution risk remains if synergy and menu uptake lag expectations.
  • Macro Funding Drag: Deep cuts in academic and pharma spending are built into the outlook, with 22% of revenue indexed to US academia and further NIH reductions possible.
  • Cost Actions Provide Flexibility: Aggressive cost cuts and cash discipline are necessary to weather revenue pressure, but may constrain innovation or commercial investment if prolonged.
  • Platform Leverage via Flow Cytometry: Samoa One’s compatibility with existing flow cytometers could transform reach and margin mix, but will require rapid market education and adoption.

Risks

Quanterix faces heightened risk from ongoing academic and pharma funding contraction, with further NIH cuts or pharma conservatism potentially driving additional revenue and margin pressure. The success of the Akoya integration and rapid uptake of Samoa One reagent kits are critical for offsetting these headwinds. Tariff exposure, while partially mitigated, could further erode margins, and competitive threats in Alzheimer’s diagnostics remain significant given larger entrants and evolving reimbursement dynamics.

Forward Outlook

For Q2 2025, Quanterix did not provide specific quarterly guidance, but expects:

  • First half revenue to comprise 45–48% of full-year total, consistent with historical seasonality
  • Continued strength in consumables and stable instrument sales, with accelerator remaining subdued

For full-year 2025, management lowered guidance:

  • Revenue of $120–$130 million, down 5–13% YoY, excluding Lucent AD diagnostic revenue
  • Non-GAAP gross margin of 50–54%, reflecting mix shift and tariff impact
  • Standalone cash usage of $35–45 million, with $20 million for emission payments

Management is prioritizing recurring revenue, cost discipline, and platform expansion, with cash flow breakeven and >$100 million cash targeted for 2026. Key swing factors include accelerator project timing, Lucent AD test launch, and Akoya synergy realization.

  • Academic funding and pharma project delays are assumed to persist through 2025
  • Upside scenarios depend on incremental consumables growth or earlier Lucent AD revenue

Takeaways

Quanterix is navigating a challenging funding environment by pivoting toward recurring consumables, menu innovation, and platform leverage, while using the Akoya merger to expand scale and synergy. The business model is shifting from lumpy capital and project cycles to a more resilient, reagent-driven approach, but execution risk around integration, new platform adoption, and macro funding remains high.

  • Consumables and Menu Innovation Now Anchor Growth: Record consumables sales and new assay launches are offsetting capital and accelerator volatility, but must continue to scale as funding pressure persists.
  • Akoya Merger and Samoa One Platform Are Pivotal Bets: The restructured deal and reagent-first strategy are designed to expand market reach and recurring revenue, but require flawless execution to deliver on synergy and margin promises.
  • Macro Headwinds Remain the Dominant Risk: Further cuts in academic and pharma spending, as well as tariff volatility, could drive additional downside if recurring revenue and cost actions do not fully offset lost capital and project sales.

Conclusion

Quanterix’s Q1 2025 marks a decisive shift to recurring consumables and platform leverage as macro headwinds deepen. The company’s ability to execute on the Akoya integration, Samoa One rollout, and Alzheimer’s diagnostics launch will determine if it can deliver on its cash flow and growth ambitions amid ongoing sector volatility.

Industry Read-Through

Quanterix’s experience is a clear signal for life sciences and diagnostics peers: recurring consumables and menu innovation are proving more resilient than capital or project-driven models in a capital-constrained environment. The aggressive reset of the Akoya merger underscores the need for pragmatic deal-making and synergy realization in today’s market. The move to make next-gen assays compatible with existing flow cytometers is a strategic template for others seeking to expand reach without relying on new instrument sales. Academic and pharma funding pressures are likely to persist, forcing the sector to prioritize recurring revenue, cost control, and platform leverage over pure growth at any cost.

QTRX Healthcare Diagnostics Proteomics Consumables Platform Synergy Cost-cutting